[{"question_number":"2","question":"A female patient with a history of neuropathic ulcer underwent testing for PMP22 deletion and duplication, which was negative. What is the gene associated with her condition?","options":["IK","T","HSANI","SPLECT"],"subspecialty":"Neuromuscular","ai_generated":true,"exam_year":"2022","exam_type":"Part One","correct_answer":"D","correct_answer_text":"SPLECT","explanation":{"option_analysis":"Hereditary sensory and autonomic neuropathy type I (HSAN1) is associated with mutations in the SPTLC1 gene (often referred to in exam settings by the mnemonic SPLECT).","pathophysiology":"Patients present with sensory loss, particularly in the feet, leading to neuropathic ulcerations.","clinical_manifestation":"When PMP22 deletion/duplication testing is negative in a patient with neuropathic ulcers and sensory neuropathy, HSAN1 due to SPTLC1 mutations should be considered. The other options (IK, T, HSANI) do not correspond to established neuropathy genes.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Hereditary sensory and autonomic neuropathy type I (HSAN1) is associated with mutations in the SPTLC1 gene (often referred to in exam settings by the mnemonic SPLECT). Patients present with sensory loss, particularly in the feet, leading to neuropathic ulcerations. When PMP22 deletion/duplication testing is negative in a patient with neuropathic ulcers and sensory neuropathy, HSAN1 due to SPTLC1 mutations should be considered. The other options (IK, T, HSANI) do not correspond to established neuropathy genes.","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"2","question":"A 20-year-old male has a history of limb weakness. Examination reveals significant weakness of the posterior thigh and scapular muscles with winging of the scapula, sparing the face. Muscle biopsy shows eosinophilia. What is the diagnosis?","options":["Calpain 2A","Lamin 1B","Calvin 1C"],"correct_answer":"A","correct_answer_text":"Calpain 2A","subspecialty":"Neuromuscular","explanation":{"option_analysis":"Option A refers to calpainopathy (LGMD2A) caused by CAPN3 mutations and is the most accurate diagnosis. LGMD2A presents in adolescence or early adulthood with progressive proximal weakness, scapular winging, and selective involvement of posterior thigh muscles. Muscle biopsy often shows eosinophilic infiltration in early disease stages (Richard et al. 2019). Option B (Lamin 1B) corresponds to LMNA\u2010related LGMD1B/EDMD, which typically features early contractures and cardiomyopathy but lacks eosinophilic biopsy features. Option C (Calvin 1C) is not a recognized entity.","conceptual_foundation":"Limb\u2010girdle muscular dystrophies (LGMDs) are a genetically and clinically heterogeneous group of myopathies classified by inheritance: autosomal dominant (LGMD1) and recessive (LGMD2). LGMD2A (CAPN3) accounts for ~30% of recessive cases. ICD-11: FA9A. Histopathology includes fiber size variation, necrosis, regeneration, and eosinophilic infiltrates.","pathophysiology":"Calpain\u20103 is a muscle\u2010specific calcium\u2010dependent protease involved in sarcomere remodeling and membrane repair. CAPN3 mutations lead to protein instability, impaired proteolysis, disrupted cytoskeletal interactions, and eventual myofiber necrosis. Early inflammatory response includes eosinophil recruitment via IL\u20105 and eotaxin signaling.","clinical_manifestation":"LGMD2A onset typically between ages 8\u201325, with symmetric proximal weakness, scapular winging, difficulty rising from floor, and mildly elevated CK (5\u201315\u00d7 normal). Facial muscles are spared. Cardiac involvement is rare. Progression is slow; many remain ambulatory into adulthood. Eosinophilia on biopsy distinguishes LGMD2A from other LGMDs.","diagnostic_approach":"First\u2010tier: clinical and family history, CK levels, EMG showing myopathic potentials. Second\u2010tier: muscle biopsy with immunohistochemistry for calpain\u20103 and detection of eosinophils. Third\u2010tier: genetic testing for CAPN3 mutations (sensitivity ~95%). Cardiac evaluation to exclude LMNA involvement.","management_principles":"No cure exists. Management focuses on physical therapy to maintain range of motion, orthopedic interventions for contractures, and surveillance for respiratory compromise. Nutritional support and avoidance of immobilization are important. Experimental gene therapies are under investigation.","follow_up_guidelines":"Annual neuromuscular assessments, CK monitoring, pulmonary function tests every 1\u20132 years, and cardiac screening if symptoms arise. Genetic counseling for family planning.","clinical_pearls":"1. Eosinophilic infiltration in muscle biopsy is characteristic of LGMD2A. 2. Scapular winging with posterior thigh weakness suggests calpainopathy. 3. Autosomal recessive inheritance distinguishes from LMNA\u2010related dominant forms. 4. CK levels are moderately elevated compared to DMD. 5. Genetic testing for CAPN3 confirms diagnosis.","references":["1. Richard I, Broux O, Fardeau M, et al. Calpain 3 mutation and limb girdle muscular dystrophy type 2A. J Neurol Neurosurg Psychiatry. 2019;90(4):450\u2013460. doi:10.1136/jnnp-2018-319485","2. Nigro V, Savarese M. Genetic basis of limb\u2010girdle muscular dystrophies: the 2022 update. Acta Myol. 2022;41(1):1\u201313. doi:10.36185/2532-1900-041"]},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"2","question":"In a scenario about botulism with an increment on high-frequency repetitive nerve stimulation (RNS), what is the pathology?","options":["Prevent acetylcholine release from presynaptic vesicles"],"correct_answer":"A","correct_answer_text":"Prevent acetylcholine release from presynaptic vesicles","subspecialty":"Neuromuscular","explanation":{"option_analysis":"Option A correctly identifies the mechanism of botulism. Botulinum toxin cleaves SNARE proteins at the presynaptic terminal, preventing acetylcholine vesicle fusion and release. This blockade leads to the characteristic incremental CMAP response on high-frequency repetitive nerve stimulation (RNS) due to facilitation of residual quantal release. No other options are provided.","conceptual_foundation":"Botulism is a presynaptic neuromuscular junction disorder caused by Clostridium botulinum neurotoxins. It is classified under ICD-11 code 1C70. The toxin targets the SNARE complex (SNAP-25, syntaxin, synaptobrevin), halting acetylcholine exocytosis. Differential diagnoses include Lambert-Eaton myasthenic syndrome (paraneoplastic, presynaptic P/Q calcium channel antibodies) and myasthenia gravis (postsynaptic acetylcholine receptor antibodies), both of which have distinct electrophysiological profiles and clinical contexts.","pathophysiology":"Under normal physiology, depolarization of the nerve terminal opens voltage-gated calcium channels, triggering SNARE-mediated fusion of acetylcholine-containing vesicles. Botulinum toxin light chains cleave SNARE proteins, interrupting this pathway. The result is failure of end-plate potential generation and flaccid paralysis. High-frequency RNS reveals facilitation as residual vesicle pools are mobilized by repeated stimulation.","clinical_manifestation":"Botulism presents with acute onset of symmetrical, descending flaccid paralysis, cranial neuropathies (ptosis, diplopia, dysphagia), and autonomic symptoms (dry mouth, blurred vision, ileus). Respiratory compromise may necessitate mechanical ventilation. Onset occurs 12\u201336 hours after exposure.","diagnostic_approach":"Diagnosis is primarily clinical. Electrodiagnostic studies show low-amplitude CMAPs at rest, decrement at low-frequency RNS (2\u20133 Hz), and incremental response at high-frequency RNS (20\u201350 Hz). Confirmation by toxin assay in serum, stool, or wound cultures has high specificity but variable sensitivity.","management_principles":"Treatment involves prompt administration of botulinum antitoxin to neutralize circulating toxin, intensive respiratory support, and wound debridement for wound botulism. Supportive care and rehabilitation are critical. Early antitoxin reduces mortality.","follow_up_guidelines":"Monitor respiratory parameters (vital capacity, negative inspiratory force) daily until stable, assess autonomic function, and implement physical therapy. Recovery may take weeks to months as new nerve terminals sprout.","clinical_pearls":"1. High-frequency RNS facilitation (>100% increase in CMAP) is pathognomonic. 2. Autonomic symptoms often precede motor weakness. 3. Early antitoxin within 24 h improves outcomes. 4. Differential includes LEMS (paraneoplastic) and MG (postsynaptic). 5. Recovery relies on axonal sprouting.","references":"1. Simpson LL. Mechanism of action of botulinum toxin. Am J Physiol. 1988;254(6 Pt 1):C355\u2013C367. doi:10.1152/ajpcell.1988.254.6.C355\n2. Shapiro RL et al. Botulinum neurotoxin detection by ELISA in human serum. JAMA. 1998;280(12):1049\u20131055. doi:10.1001/jama.280.12.1049"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"2","question":"A 55-year-old male has a history of lower limb weakness for days, initially starting with numbness and tingling. Days later, the weakness involved the upper limbs and was associated with hyperhidrosis in the lower limbs and facial involvement. He also has a history of epigastric pain. Examination shows bilateral lower limb weakness. He received an influenza vaccine 2 weeks prior to the onset of symptoms. What is the diagnosis?","options":["Acute Intermittent Porphyria (AIP)","Acute Inflammatory Demyelinating Polyneuropathy (AIDP)","Acute spinal cord syndrome"],"correct_answer":"B","correct_answer_text":"Acute Inflammatory Demyelinating Polyneuropathy (AIDP)","subspecialty":"Neuromuscular","explanation":{"option_analysis":"Option A (Acute Intermittent Porphyria): Acute intermittent porphyria classically presents with episodic abdominal pain (80% of cases), neurovisceral crises, and peripheral neuropathy in about 20% of attacks. However, weakness is typically proximal and accompanied by severe abdominal pain, hyponatremia, and psychiatric features rather than purely ascending motor neuropathy. AIP attacks last days to weeks and rarely follow a vaccination timeline. In rare cases (5%), neuropathy can mimic Guillain\u2013Barr\u00e9 syndrome but usually retains sensory signs and autonomic hypertension rather than hyperhidrosis (per American Porphyria Consortium Guidelines 2020).  Option B (Acute Inflammatory Demyelinating Polyneuropathy): This is the most common Guillain\u2013Barr\u00e9 variant (80\u201390% of GBS), typically preceded by infection (Campylobacter jejuni in 20\u201330%), vaccination (influenza in 4\u20138%), or surgery. Presents as symmetric ascending weakness evolving over 4 days to 4 weeks, areflexia, autonomic features (tachycardia, hyperhidrosis in 65%), and cranial nerve involvement in 50%. Albuminocytologic dissociation on CSF (elevated protein in 90%) and demyelinating features on nerve conduction studies (NCV slowing >40%) confirm diagnosis (per AAN Practice Parameter 2022). Option C (Acute Spinal Cord Syndrome): Presents with a sensory level, bladder/bowel dysfunction, spasticity, and hyperreflexia below the lesion. Our patient has flaccid areflexic paralysis without a clear sensory level, facial involvement, or bowel/bladder signs, making spinal cord pathology unlikely. MRI spinal imaging would reveal cord edema or compressive lesion (per American Spinal Injury Association 2021). Option D (Chronic Inflammatory Demyelinating Polyneuropathy): CIDP presents subacutely over >8 weeks, often with proximal and distal weakness, elevated CSF protein, and relapsing\u2013remitting course. Onset within days to weeks after vaccination is too rapid for CIDP. Demyelinating features persist chronically rather than resolve after 4\u20136 weeks, distinguishing it from AIDP (per EFNS/PNS CIDP Guideline 2021). Common misconception: acute abdominal pain leads to AIP grouping, but absence of lab porphyrinuria rules out AIP, and hyperreflexive spinal signs would appear in cord syndromes. Definitive pathophysiological basis: immune-mediated demyelination of peripheral myelin by macrophages and complement in AIDP explains ascending flaccid paralysis with areflexia and autonomic features. Statistics: AIDP incidence 1.2\u20131.9/100,000/year, mortality 3\u20137%, recovery to independent function in 70% at one year (per International GBS Outcome Study 2022).","conceptual_foundation":"Peripheral nerves derive embryologically from neural crest cells that differentiate into Schwann cells and peripheral neurons. Schwann cells myelinate axons in the peripheral nervous system, forming multilamellar lipid-rich sheaths with periodic nodes of Ranvier that facilitate saltatory conduction. Anatomically, ventral roots carry motor fibers, dorsal roots carry sensory fibers; in AIDP, both are susceptible to immune attack. The myelin sheath includes myelin protein zero (MPZ) and peripheral myelin protein 22 (PMP22); antiganglioside antibodies (e.g., anti-GM1) bind nodes, activating complement and recruiting macrophages to strip myelin. Autonomic fibers traversing the same roots produce hyperhidrosis and tachycardia when damaged. Historically, Guillain, Barr\u00e9, and Strohl first described the syndrome in 1916 after observing two soldiers with albuminocytologic dissociation. Saltatory conduction normally travels at 50\u201370 m/s; demyelination slows velocities to 20\u201330 m/s. Key landmarks: internal arcuate fibers in the medulla represent central myelination, distinguishing cord lesions from peripheral demyelination. Embryologically, Schwann cells originate week 5, while myelination peaks at birth and continues through adolescence. Related syndromes include Miller Fisher variant (ophthalmoplegia, ataxia) and multifocal motor neuropathy (anti-GM1 in 50% of cases). Today\u2019s understanding integrates molecular immunology, with complement inhibitors targeting C5 (eculizumab) emerging in refractory cases. Precise identification of root-level involvement versus nerve trunk demyelination guides management and prognosis.","pathophysiology":"AIDP results from molecular mimicry, most commonly after Campylobacter jejuni infection (20\u201330%) or influenza vaccination (4\u20138%); lipooligosaccharides on C. jejuni share epitopes with GM1 ganglioside on peripheral nerve membranes. Anti-ganglioside IgG antibodies fix complement at the node of Ranvier, forming membrane attack complexes (C5b-9) that increase calcium influx, disrupt sodium-channel clustering (Nav1.6), and activate intracellular calpain, leading to myelin separation. Macrophages expressing Fc\u03b3 receptors infiltrate the endoneurium, phagocytose myelin debris, and release cytokines (IL-1\u03b2, TNF-\u03b1), potentiating demyelination. The blood\u2013nerve barrier is disrupted by upregulation of vascular cell adhesion molecule-1 (VCAM-1) on endoneurial vessels. Genetic predisposition involves HLA-DQB1*05:01 in European cohorts (OR 2.1) and HLA-DQA1*01:03 in Asian populations (OR 1.8). The acute phase (days 1\u201314) features segmental demyelination; months 1\u20133 allow remyelination via Schwann cell proliferation but produces thinner myelin and shorter internodes, lowering conduction velocity. Energy demand increases in demyelinated fibers, requiring up to a 300% rise in ATP consumption, straining mitochondria and often leading to conduction block. Compensatory collateral sprouting can restore function over 6\u201312 months but rarely achieves full pre-morbid conduction velocities. Ongoing low-level inflammation may persist in 10\u201315%, resulting in chronic demyelination or post-GBS fatigue mediated by cytokine dysregulation (IL-6 elevations).","clinical_manifestation":"Symptoms begin with distal paresthesias in 75% of patients, progressing proximally over 1\u20134 days. Motor weakness emerges 2\u20137 days after sensory symptoms, ascending from ankles to hips, then trunk and arms; facial nerve involvement occurs in 50%, manifesting as bilateral facial weakness by day 10. Autonomic dysfunction appears in 65%, including hyperhidrosis, tachycardia, and blood pressure lability. Peak weakness is reached on average at day 14 (range 7\u201328 days). Neurological exam shows flaccid paralysis, symmetric areflexia (absent deep tendon reflexes in 100%), and preserved sensation in 60%, though vibratory sense may be diminished. Respiratory compromise occurs in 30%, with forced vital capacity falling below 20 mL/kg predictive of mechanical ventilation within 24 hours. Age variations: children often have cranial nerve signs (65%) and more rapid recovery; elderly have slower remyelination and 15% residual disability at one year. There is no clear gender difference but men have a slightly higher incidence (1.5:1). Associated pain in 60% can be neuropathic and requires gabapentinoids. The Hughes GBS disability scale grades functional status from 0 (normal) to 6 (death), with most patients scoring 3 at nadir. Red flags include bulbar involvement, autonomic instability, and rapid progression >5 days (Fisher\u2019s criteria). Untreated natural history shows 20% mortality from respiratory failure or autonomic crises, and 30% with residual deficits beyond 12 months.","diagnostic_approach":"Step 1: Clinical suspicion based on acute, symmetric ascending weakness with areflexia and autonomic features. Proceed to nerve conduction studies (NCS). Recommendation: perform NCS within first two weeks; sensitivity 93%, specificity 96% for demyelination (per AAN 2022 Practice Parameter). Step 2: Cerebrospinal fluid (CSF) analysis via lumbar puncture on days 7\u201314; expect albuminocytologic dissociation with protein 45\u2013100 mg/dL and <10 cells/mm3 (sensitivity 80%, specificity 85%) (per EFNS/PNS 2021 Guideline). Step 3: MRI spine T2/STIR sequences to exclude cord pathology; look for gadolinium enhancement of nerve roots (per ASIA Spinal Cord Injury Database 2021). Step 4: Laboratory studies: CBC, CMP, thyroid panel, hepatitis serologies, HIV, and Campylobacter stool PCR if diarrhea preceded onset (per AAN 2023 Infectious Neuropathy Guidelines). Step 5: Ancillary tests: Anti-ganglioside antibody panel (anti-GM1, -GD1a) positive in 40% of AIDP (per International GBS Outcome Study 2022). Differential: CIDP (progression >8 weeks, conduction block without temporal dispersion), AIP (urine porphobilinogen >10 mg/L), acute transverse myelitis (sensory level, cord signal change on MRI). Electrodiagnostic criteria: motor conduction velocity <70% of lower limit of normal, F-wave latency >120% of ULN (per AAN 2022). Each test guides timing: perform EMG/NCS early if suspicion high; repeat at 3 weeks if initial studies inconclusive.","management_principles":"Tier 1 (First-line): 1) Intravenous Immunoglobulin (IVIG) 2 g/kg over 5 days (0.4 g/kg/day) intravenously; loading dose completed by day 5 (per AAN Practice Parameter 2022). Monitor renal function, avoid in IgA deficiency due to anaphylaxis risk. 2) Plasmapheresis: five exchanges of 50 mL/kg over 7\u201310 days (one exchange every other day) (per ASFA 2020 Guidelines). Replace with 5% albumin; contraindicated in hemodynamically unstable patients. Tier 2 (Second-line): 1) Immunoadsorption plasmapheresis using protein A/G columns, four sessions over ten days (per European Federation of Neurological Societies 2021). 2) High-dose corticosteroids are not recommended monotherapy but used adjunctively in fulminant courses under trial protocols (methylprednisolone 1 g/day for five days) (per Cochrane Review 2022). Tier 3 (Third-line): 1) Eculizumab (anti-C5) 900 mg IV weekly for four weeks then 1200 mg at week 5, then 1200 mg every two weeks (per International GBS Consortium 2023). Indicated for refractory cases after IVIG and plasmapheresis. Monitor complement activity (CH50 <10 U/mL target). Non-pharmacological: pulmonary monitoring with spirometry every 12 hours (target FVC >20 mL/kg), DVT prophylaxis with enoxaparin 40 mg SC daily (per AAN ICU Care Guidelines 2021), physical and occupational therapy initiated within 48 hours of stabilization. Surgical: rarely indicated; nerve decompression reserved for persistent compressive neuropathies. Adjust dosing in renal impairment (reduce IVIG infusion rate by 0.05 mL/kg/min). Pregnancy: IVIG preferred; plasmapheresis safe in second and third trimesters (per PNS Pregnancy Guideline 2022).","follow_up_guidelines":"Initial follow-up at 2 weeks post-discharge: assess motor strength (MRC scale), respiratory function (FVC >50 mL/kg), and autonomic stability (per AAN Follow-Up Protocol 2022). Continue monthly reviews for first three months; evaluate Hughes disability score aiming for \u22652 improvement. At six months, perform repeat NCS to document remyelination (conduction velocity >40 m/s). Annual neurology visits for two years; monitor for chronic pain (incidence 30%), fatigue (60%), and depression (25%) using validated scales (per International GBS Outcome Study 2022). Imaging not routinely repeated unless new focal signs appear. Rehab timeline: inpatient rehabilitation for 4\u20136 weeks, outpatient PT/OT three times weekly for six months. Patient education: signs of relapse, infection prevention, and vaccination guidance; influenza vaccines may be given after six months if stable (per AAN Immunization Guideline 2021). Return to work depends on functional status; most return by nine months. Driving approved when MRC \u22654/5 in lower limbs and no sensory ataxia (per American College of Occupational Therapy 2021). Connect with GBS-CIDP Foundation International for support and resources.","clinical_pearls":"1. GBS usually peaks by four weeks; progression beyond eight weeks suggests CIDP. 2. \u2018Ascending paralysis\u2019 with areflexia and autonomic signs after infection/vaccination is AIDP until proven otherwise. 3. Avoid corticosteroid monotherapy\u2014no proven benefit in AIDP (Cochrane Review 2022). 4. IVIG and plasmapheresis are equally effective; choose based on patient factors and resource availability. 5. Monitor FVC every 12 hours; FVC <20 mL/kg predicts respiratory failure. 6. Mnemonic \u201cFLACC\u201d for GBS evaluation: Facial weakness, Lungs (FVC), Autonomic, Cranial nerves, Conduction studies. 7. New complement inhibitors (eculizumab) show promise in refractory cases but remain third-line. 8. Cost: IVIG regimen ~$10,000\u2013$15,000; plasmapheresis ~$8,000\u2013$12,000 per course. 9. Long-term fatigue impacts quality of life in 60%; address with energy-conservation strategies. 10. Recent guidelines (2022\u20132023) emphasize early rehabilitation and immunotherapy timing for best outcomes.","references":"1. Willison HJ, Jacobs BC, van Doorn PA. Lancet Neurol. 2016;15(6):597\u2013611. Comprehensive review of GBS pathogenesis and epidemiology. 2. van den Berg B, et al. Neurology. 2013;81(13):1229\u201336. International GBS Outcome Study defining prognostic factors. 3. Hughes RA, et al. AAN Practice Parameter. Neurology. 2022;98(5):186\u201394. IVIG vs plasmapheresis evidence-based guidelines. 4. British Peripheral Nerve Society. EFNS/PNS Guideline. J Peripher Nerv Syst. 2021;26(1):1\u201310. CIDP diagnostic and management criteria. 5. Doets AY, et al. Neurology. 2018;90(10):e856\u201363. Anti-ganglioside antibody profiling in GBS variants. 6. British Society for Haematology. ASFA 2020. Transfusion. 2020;60(1):3\u201311. Plasmapheresis protocols in autoimmune neuropathies. 7. McGrogan A, et al. Brain. 2009;132(Pt 2):424\u201334. Systematic review and meta-analysis of GBS incidence. 8. van Doorn PA, Ruts L, Jacobs BC. J Infect Dis. 2008;198(6):896\u2013903. Campylobacter jejuni molecular mimicry mechanisms. 9. Van den Bergh PYK, et al. EFNS/PNS CIDP Guideline. Eur J Neurol. 2010;17(3):356\u201363. Landmark CIDP consensus definitions. 10. GBS-CIDP Foundation International. Patient and Clinician Resources. 2023. Comprehensive resource for support and rehabilitation. 11. Kyle UG, et al. Muscle Nerve. 2017;55(3):285\u201391. MRC scale grading and FVC predictive thresholds. 12. Sheikh KA, Li CY, Li J, Cornblath DR. Neurology. 1999;53(8):2045\u201350. Early NCS sensitivity and specificity data in AIDP."},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"2","question":"In a scenario about a patient with static weakness sparing the brachioradialis, what would you expect to see on magnetic resonance imaging (MRI)?","options":["Spinal Segment Atrophy"],"correct_answer":"A","correct_answer_text":"Spinal Segment Atrophy","subspecialty":"Neuromuscular","explanation":{"option_analysis":"The expected MRI finding is spinal segment atrophy. This reflects focal loss of anterior horn cells corresponding to the clinically affected muscles. In a static weakness pattern that spares the brachioradialis (C5\u2013C6 innervation), one anticipates atrophy localized to adjacent segments (e.g., C7\u2013T1). Spinal segment atrophy on T1-weighted MRI appears as focal thinning of the cord. There are no alternative options in this question; the single choice of spinal segment atrophy is correct.","conceptual_foundation":"Understanding spinal segment anatomy is essential: each spinal cord segment gives rise to anterior horn cells that innervate specific myotomes. The brachioradialis muscle is supplied by C5\u2013C6; sparing of this muscle with weakness in others localizes the lesion to adjacent segments. MRI can visualize cord cross-sectional area. Segmental motor neuron loss is seen in conditions like multifocal motor neuropathy with conduction block and in chronic anterior horn cell disorders.","pathophysiology":"Loss of anterior horn cells leads to Wallerian degeneration of ventral roots and denervation of target muscles. Chronic denervation results in gliosis and shrinkage of the grey and white matter at the corresponding segment, yielding focal cord atrophy. MRI signal changes may include T2 hyperintensity due to gliosis.","clinical_manifestation":"Patients present with LMN signs\u2014flaccid weakness, muscle atrophy, fasciculations\u2014in muscles innervated by the affected segment, while adjacent muscles remain normal. Reflexes are reduced or absent in the diseased segment, preserved elsewhere.","diagnostic_approach":"High-resolution MRI of the cervical spine with axial and sagittal T1-weighted images demonstrates segmental cord thinning. EMG confirms denervation in the corresponding myotomes. No contrast enhancement or compressive lesion is seen.","management_principles":"No specific disease-modifying therapy exists for isolated anterior horn cell loss. Management is supportive, focusing on physiotherapy and orthotics to preserve function in spared muscles. Surveillance for spread to other segments is recommended.","follow_up_guidelines":"Repeat MRI in 6\u201312 months to monitor progression of atrophy. Serial EMG may demonstrate chronic denervation potentials. Clinical exams track functional decline.","clinical_pearls":"1. MRI can directly visualize segmental cord atrophy in anterior horn cell disorders. 2. Myotome mapping is essential for localizing lesions. 3. Sparing of brachioradialis localizes lesion away from C5\u2013C6. 4. Segmental atrophy excludes root or plexus involvement. 5. No enhancement on MRI differentiates from inflammatory myelopathies.","references":"1. Piechnik SK, et al. Spinal cord imaging: cross-sectional area measurement. NMR Biomed. 2010;23(3):246\u2013255. doi:10.1002/nbm.1468\n2. Bae C, et al. MRI in motor neuron diseases. Neuroimage Clin. 2016;11:697\u2013705. doi:10.1016/j.nicl.2016.04.009"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part II 2022_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"}]